Resilience to acquire Bluebird facility, partner on vector manufacturing

By The Science Advisory Board staff writers

July 28, 2021 -- Bluebird Bio and National Resilience have formed a strategic alliance to accelerate the early research, development, and delivery of next-generation cell therapies.

As part of the agreement, Resilience will acquire Bluebird's Research Triangle clinical and commercial suspension lentiviral vector manufacturing facility in Durham, NC, and retain all employees (more than 100) at the site. The 125,000-sq-ft facility includes drug substance and drug product production suites, quality control testing laboratories, and warehousing space, as well as additional room for future expansion. Resilience has committed to investing in new technologies and expanding the workforce as part of its mission to build a digitally connected, end-to-end biomanufacturing ecosystem, it said.

Bluebird will receive $110 million from Resilience upon closing the transaction.

Resilience will continue to support vector supply for both Bluebird and 2seventy bio (a spinoff oncology cell therapy company that is expected to launch by the end of 2021). The two companies will continue to collaborate on the next phase of 2seventy's pipeline, contributing expertise in cell therapy development and manufacturing.

The companies are also finalizing an agreement to establish partner programs that will share expenses and revenue for successfully commercialized oncology products and the establishment of a next-generation manufacturing R&D collaboration.

Resilience acquires Ology Bioservices
Resilience has purchased biologic drug substance manufacturing firm Ology Bioservices; terms of the deal were not disclosed.
Resilience expands U.S. biologics manufacturing footprint
Resilience is building its North American presence for biologics manufacturing through the acquisition of two commercial manufacturing facilities, one...
Development 'cookbooks' could speed up gene therapy
Great strides have been made in the development of gene editing tools in the past decade, but translating the technology into real therapies to treat...
Bluebird Bio to split business
Bluebird Bio announced that it will separate its severe genetic and oncology businesses into two distinct and independent publicly traded companies. Bluebird...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter